PRODUCTS & INNOVATION
ABBOTT ADDS TO STRUCTURAL HEART TECH
CE Mark approval for two devices provides new options for hard-to-treat heart valve conditions.
Apr 17 2020
Millions of people have heart valve conditions, yet less than 1% receive the standard of care, open-heart surgery, because they’re often too ill or frail for the invasive procedure.1,2,3
Two of Abbott’s newest structural heart devices — the Tendyne* Transcatheter Mitral Valve Implantation System and our TriClip** Transcatheter Tricuspid Valve Repair System — recently received CE Mark approvals and are expected to help fill these gaps in treatment.
Tendyne replaces a leaky mitral valve on the heart’s left side and complements MitraClip, Abbott’s market-leading device for repairing a leaky mitral valve, while TriClip repairs a faulty tricuspid valve on the right side of the heart.
In addition to providing much-needed treatment options, the CE Mark approvals also further boost Abbott’s transcatheter mitral solution portfolio — the world’s largest4 — and potentially broaden the company’s user base.
“We’re entering a renaissance in the treatment of structural heart diseases and Abbott is building the broadest portfolio of structural heart solutions in the world,” said Michael Dale, senior vice president of Abbott’s Structural Heart business.
Breadth of portfolio
Structural heart conditions refer to defects or abnormalities in the heart’s valves, walls and/or muscle. These heart problems affect tens of millions of people worldwide, and that number’s projected to grow as the population continues aging.
Abbott’s $1.4 billion in 2019 structural heart sales, highlights the company’s strength in the market as well as its potential to expand. Abbott’s structural heart business has now grown double-digits for the last three years in a row (since the business’s inception).
Expected to help sustain the portfolio’s momentum is Abbott’s robust pipeline, including long-term growth drivers Tendyne and TriClip.
TriClip’s development was inspired by MitraClip’s proven clip-based therapy, but TriClip has a differentiated delivery system uniquely designed for the tricuspid valve. The device clips the leaky tricuspid valve leaflets in place, enabling the valve to close again and the heart to function properly.
Abbott’s Tendyne enables physicians to replace the mitral valve when repair or more invasive surgery aren’t options.
Both Tendyne and TriClip spotlight Abbott’s focus on providing physicians a continuum of care for treating structural heart conditions across diverse patient populations.
“We want to give doctors the options they need to address various structural heart issues,” said Dale.
Visit the company’s structural heart site for a closer look at how Abbott’s game-changing heart tech is helping people live healthier.
For U.S. important safety information on MitraClip, visit: https://www.structuralheartsolutions.com/us/mitraclip-isi.
*The Tendyne Transcatheter Mitral Valve Implantation System is an investigational device only in the U.S.
**The TriClip Transcatheter Tricuspid Valve Repair System is an investigational device only in the U.S.
1. Nkomo, et al. Burden of valvular heart diseases. Lancet. 2006.
2. U.S. Census Bureau. Statistical Abstract of the United States: 2012. Table 7.
3. Stuge O, Liddicoat J. Eme rging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg. 2006;132:1258–126.
4. Internal data at Abbott.
Abbott Launches First Glucose Sport Biosensor for Athletes
Reskilling: A Key to Abbott's Success
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.